Smith & Nephew Dermagraft Will Remain On OPPS Pass-Through List In 2004
This article was originally published in The Gray Sheet
Executive Summary
CMS is granting Smith & Nephew's request that its Dermagraft bio-engineered skin for treating hard-to-heal diabetic foot ulcers be kept on the transitional "pass-through" payment list through 2004, allowing at least two years of pass-through eligibility as a biologic
You may also be interested in...
Medicare Revisits “New Technology” Outpatient Payment Levels For 2002
FDG-PET will be reimbursed at $1,375 per procedure under CMS' hospital outpatient prospective payment system update for 2002. The payment rate will go into effect April 1
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.